Corpus Intelligence IC Memo — STEWARD ST. ANNES HOSPITAL 2026-04-26 03:43 UTC
IC Memo — STEWARD ST. ANNES HOSPITAL
Investment Committee Memorandum | MA | 175 beds | Grade C | EBITDA uplift $23.7M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

STEWARD ST. ANNES HOSPITAL

CCN 220020 | BRISTOL, MA | 175 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

STEWARD ST. ANNES HOSPITAL is a 175-bed suburban community hospital in BRISTOL, MA with $322.3M in net patient revenue and a 12.8% operating margin. The hospital serves a payer mix of 38.0% Medicare, 9.5% Medicaid, and 52.4% commercial.

Thesis: Turnaround. Our ML models identify $23.7M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 12.8% to 20.2% (+736bps).

Net Revenue HCRIS$322.3M
Current EBITDA COMPUTED$41.3M
Operating Margin COMPUTED12.8%
Occupancy HCRIS66.6%
Revenue / Bed COMPUTED$1.8M
Net-to-Gross HCRIS40.3%
Distress Probability ML46.5%

2. Market Context & Competitive Position

99
MA Hospitals
-12.2%
State Median Margin
55
Comparable Hospitals

MA has 99 Medicare-certified hospitals with a median operating margin of -12.2%. The target's margin of 12.8% places it above the state median. Among 55 size-comparable peers (88-350 beds), the median margin is -11.3%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (88-350), prioritizing same-state peers. 55 hospitals in the comp set.

HospitalStateBedsRevenueMargin
STEWARD ST. ANNES HOSPITAL (Target)MA175$322.3M12.8%
LAHEY CLINIC HOSPITAL INC.MA345$991.1M-4.2%
NEWTON WELLESLEY HOSPITALMA216$624.3M-4.7%
CAPE COD HOSPITALMA239$620.3M-1.3%
BERKSHIRE MEDICAL CENTERMA238$522.9M-12.9%
NORTH SHORE MEDICAL CENTERMA268$503.5M-12.9%
STEWARD ST. ELIZABETHS MEDICALMA244$428.5M0.7%
BEVERLY HOSPITALMA261$410.6M-1.6%
SAINT VINCENT HOSPITALMA232$404.2M0.2%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $23.7M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$6.8M+210bp18mo
Cost to Collect4.5%2.5%$6.4M+200bp12mo
Denial Rate Reduction12.0%6.5%$6.4M+198bp12mo
A/R Days Reduction5200.0%3800.0%$3.9M+122bp9mo
Clean Claim Rate88.0%96.0%$206K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$6.8M
Cost to Collect
$6.4M
Denial Rate Reduction
$6.4M
A/R Days Reduction
$3.9M
Clean Claim Rate
$206K
Total EBITDA Uplift$23.7M
Current EBITDA$41.3M
+ RCM Uplift+$23.7M
Pro Forma EBITDA$65.0M
Current Margin12.8%
Pro Forma Margin20.2%
WC Released (1x)$12.4M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$63.5M$509.4M8.03x51.7%
Base (11x exit)10.0x11.0x$63.5M$580.9M9.15x55.7%
Bull Case9.0x11.0x$57.1M$679.9M11.90x64.1%
Bull (12x exit)9.0x12.0x$57.1M$758.5M13.28x67.7%
Bear Case11.0x10.0x$69.8M$370.2M5.30x39.6%
Bear (11x exit)11.0x11.0x$69.8M$429.8M6.16x43.8%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumStandard execution riskRCM improvement requires management buy-in and 12-18 month implementation timeline

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 55 hospitals with 88-350 beds
  • Same-state prioritization (n=56)
  • Comp margins: P25=-18.4% / P50=-11.3% / P75=-1.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.